Product Code: RP-ID-10151920 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151920
Market Overview:
Global Clinical Next-Generation Sequencing Industry Market Research 2030
"Clinical Next Generation Sequencing Market is projected to mark value of USD 12 billion by the end of 2022, expected to mark CAGR of 20% over the period 2022-2030. Next Generation Sequencing (NGS) is a technology for sequencing the nucleotides of a specific DNA sample. This enables DNA or RNA sequencing in less time and at a lower cost. This market growth is primarily driven by technological advances in sequencing technology, growth in genome mapping software, and the rise of drug discovery platforms required for NGS technology. Additionally, NGS products are being driven by government growth initiatives for large-scale gene sequencing projects and the advent of cloud computing as a potential data management service.
THE RISE OF GENOME MAPPING SOFTWARE IS DRIVING THE NEXT GENERATION SEQUENCING:
Low sequencing costs allow governments around the world to use genetic analysis as an important part of disease diagnosis and personalized medicine. Worldwide. For example, in May 2018, the Australian Government launched The Future of Australian Genomics Health Mission, a general genomics research project. The mission began with an investment of approximately $370 million to expand access to new research capabilities, clinical trials and technologies to improve the healthcare industry. Similarly, China launched the Genome 100,000 project in December 2017. By sequencing the genomes of 100,000 people from diverse racial and ethnic regions across China, it aims to study disease transmission, affected environments, and interactions in populations. Moreover, the proliferation of genome mapping programs increased individual medical studies in 2016. The European Union (EU) announced the Horizon 2020 program with an investment of $88.5 billion ($80 billion). About 10% (900 million)) development and support of individual health projects. Similarly, China plans to invest 9 billion dollars (60 billion yuan) in research and development of five personalized medicines in 2016.
Growth in government initiatives for large-scale gene sequencing projects is supporting the market growth. Governments are investing in pharmaceutical manufacturing, research and clinical diagnostics because of the need for investment in NGS capabilities, a wide range of applications, and an increasing trend towards personalized medicine. Here is an example of a large-scale genome sequencing project. In May 2018, the Australian Government announced an investment of $372 million over 10 years to sequence 200,000 participants in the future of the Genome Health Mission. ) in 2018 announced a partnership project called "2020-2020". The plan aims to sequence normal tumors and tissues from African American patients in 2020 to better understand African American cancers. The Institute for Health Research, in partnership with Genome Canada, a nonprofit organization that uses genome-based technology, is investing $162 million over four years to support 15 genome-based, accurate health projects.
KEY FINDINGS OF GLOBAL NEXT GENERATION SEQUENCING MARKET STUDY :
Sequencing will be the highest demand by 2022. Due to the power of this technology, the sequencing segment of the global target market will be smaller than any other sequencing (in 2019) which should be next-generation sequencing. Technology Cost indexing technology, the ability to generate verifiable amounts of data with reliable results.
.
SYNTHETIC SEQUENCING IS EXPECTED TO GROW THE FASTEST IN THE NEXT GENERATION SEQUENCING MARKET BY 2025:
Based on this technology, synthetic segment-based sequencing is expected to hold the largest share in the overall next-generation sequencing market in 2020. The main contribution of this sector is due to the high accuracy and error-free performance of SBS technology in DNA sequencing and the greater integration of this technology into NGS equipment. The availability of numerous SBS technology products and the introduction of products based on SBS technology are supporting market growth.
FASTEST GROWING NEXT GENERATION SEQUENCING MARKET TO 2025 DIAGNOSTIC APPLICATION:
Diagnostic applications are based on the applications that account for the largest share of the global next-generation sequencing market and are growing primarily for cancer and clinical applications. According to the World Health Organization (WHO), their number is growing. disease treatment procedures. The International Agency for Research on Cancer (IARC) reported 18.1 million new cancer cases in 2018, and is expected to increase to 24.1 million and 29.5 million, respectively, by 2030. Therefore, in 2040, the demand for cancer therapeutics, related drugs and genes is expected to increase. The increasing number of analytical methods to detect gene expression and functional abnormalities will ultimately lead to the next-generation sequencing technology market.
CLINICAL DIAGNOSTIC LABORATORIES DOMINATE THE GLOBAL NEXT GENERATION SEQUENCING MARKET :
The clinical diagnostic laboratory segment is expected to become the largest next-generation sequencing market in 2020. A growing group of cancer patients visit our labs for diagnostic and therapeutic capabilities for these end users. An easily accessible segment of the Next Generation Sequencing Market. Improving healthcare infrastructure in developed and developing countries supports the growth of the next-generation laboratory diagnostic sequences market.
MAJOR PLAYERS :
The report includes a comprehensive assessment of the competitive landscape of key strategic developments adopted by major market players in the industry in the past 4 years (2016-2019). The main players outlined in the global next-generation sequencing market report are Illumina, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Thermo Fisher Scientific Inc.. (EE. UU.) 〠Qiagen NV (Países Bajos) 〠PerkinElmer, Inc. (EE. UU.) 〠F. Hoffmann-La Roche AG (Suiza) 〠10X Genomics, Inc. (EE. UU.) 〠Pacific Biosciences(EE. UU.), Oxford Nanopore Technologies Ltd (Reino Unido), Beckman Coulter, Inc. (EE. UU.), GenapSys, Inc. (EE. UU.), New England Biolabs, Inc. (EE. UU.), PierianDx (EE. UU.) Y BGI Genomics .
REPORT SCOPE :
Next-generation sequencing market, consumables by type, sample preparation, DNA fragmentation and amplification library preparation and target enrichment quality control, other consumables (Note: other consumables include vials, pipettes, containers, trays, etc.) Tube, etc.) NGS platform/instrument Illumina NGS platform/instrument/instrument MiSeq Next Seq Mini Seq Nova Seqi Seq Thermo Fisher Scientific NGS platform/instrument Ion PGMIon Proton Ion S5 & S5XLPacific Biosciences platform/instrument NGS PacBio RSpore sequencing software .
The latest generation of NGSSystems NGSSystems NGS sequencing instruments Exome Note: Other sequencing methods include RNA sequencing, de novo sequencing, degraded group sequencing, sequencing miRNA g, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing) Next-generation sequencing market, by technology synthetic sequencing ion semiconductor sequencing Link sequencing Single molecule real-time sequencing Nanopore sequencing and others (Note: other sequencing technologies, DNA bead nano-sequencing, including nanoball sequencing). And true single-molecule sequencing (tSMS)) next-generation sequencing market, according to the application of clinical applications oncology, reproductive health diagnosis, non-invasive prenatal testing vector testing in vitro fertilization newborns testing cardiovascular and other (Note: other clinical applications include testing the genetics of the nervous system Aberration diseases, rare diseases, metabolism) and immune diseases and food-borne diseases) research applications, drug discovery, agriculture and animal research, others (Note: other research applications include food microbiology, beverage industry microbiota analysis and environmental research) Next-generation sequencing market , By end-user clinical diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutions, others (Note: other end users include n forensic departments, food companies and hospitals). "
Related Reports
Proof of Quality & Reliability
